The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Long-Acting Somatostatin Analog Therapy of Acromegaly: A Meta-Analysis
Open accessAbstract
CONTEXT: Although considerable data exist on the use of long-acting somatostatin analogs to treat acromegaly, their reported efficacy differs substantially among trials. OBJECTIVE: We conducted a meta-analysis to derive definitive estimates of their efficacy for biochemical control and tumor shrinkage. DATA SOURCES: A search of literature was conducted through 2003, primarily via PubMed. STUDY SELECTION: Inclusion criteria, met in 44 trials, included at least 3 months of secondary octreotide long-acting release (LAR) or lanreotide slow release (SR) therapy or of primary octreotide LAR, lanreotide SR, or sc octreotide therapy and clearly reported data on biochemical efficacy and/or tumor shrinkage. Fifty other trials screened did not meet analysis inclusion criteria. DATA EXTRACTION: Data were extracted by three independent observers. DATA SYNTHESIS: Among subjects not selected for somatostatin analog responsiveness before study entry, both GH efficacy criteria and IGF-I normalization were met in a greater proportion of those treated with octreotide LAR vs. lanreotide SR (GH: B = 0.2310, P = 0.016; IGF-I: B = 0.2325, P = 0.007). Prestudy selection for somatostatin analog responsiveness was not a significant predictor of meeting GH efficacy criteria (B = 0.0992; P = 0.12). Preselection was a positive predictor of IGF-I normalization rate (B = 0.1213; P = 0.04), which was greater among preselected than unselected subjects (B = 0.1472; P = 0.0475). IGF-I normalization occurred in a greater proportion of secondary octreotide LAR- vs. primary octreotide-treated subjects (B = 0.2056; P = 0.009). The odds of tumor shrinkage more than 10% were lower in the unselected vs. preselected subjects. However, the effect of drug type was an important predictor of shrinkage; such that regardless of preselection or not, the odds of shrinkage with lanreotide SR were lower than with octreotide LAR (P = 0.003). Shrinkage greater than 10% occurred in a higher percentage of primary octreotide LAR-treated vs. primary octreotide sc-treated subjects (odds ratio = 9.4; P < 0.0001). The overall rate of tumor increase was 1.4%. CONCLUSIONS: In this meta-analysis, we have shown that the efficacy of octreotide LAR is greater than lanreotide SR among subjects unselected for prior somatostatin analog responsiveness. Preselection is a significant positive predictor of IGF-I normalization and is associated with increased odds of tumor shrinkage, which is also greatest with octreotide LAR. Biochemical efficacy is similar, but tumor shrinkage is greater when these drugs are given as primary vs. secondary therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bevan, J. S., Atkin, S. L., Atkinson, A. B., Bouloux, P.-M., Hanna, F., Harris, P. E., James, R. A., McConnell, M., Roberts, G. A., Scanlon, M. F., et al. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2001-012012 · Cited by 279
Vance, M. L., & Harris, A. G. (1991) · Archives of Internal Medicine · doi:10.1001/archinte.1991.00400080073013 · Cited by 249
BARKAN, A. L., BEITINS, I. Z., & KELCH, R. P. (1988) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-67-1-69 · Cited by 239
Effect of Octreotide Pretreatment on Surgical Outcome in Acromegaly
Colao, A., Ferone, D., Cappabianca, P., De, M. D. B., Marzullo, P., Monticelli, A., Alfieri, A., Merola, B., Calì, A., de Divitiis, E., et al. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.10.3308 · Cited by 234
Cozzi, R., Attanasio, R., Montini, M., Pagani, G., Lasio, G., Lodrini, S., Barausse, M., Albizzi, M., Dallabonzana, D., & Pedroncelli, A. M. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030110 · Cited by 190
Three Year Follow-Up of Acromegalic Patients Treated with Intramuscular Slow-Release Lanreotide1
Caron, P. J., Morange, I., Cogne, M., & Jaquet, P. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.1.3714 · Cited by 179
Colao, A. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.6.2779 · Cited by 179
Sandostatin LAR in Acromegalic Patients: Long Term Treatment
Fløgstad, A. K., Halse, J., Bakke, S. J., Lancranjan, I., Marbach, P., Bruns, C., & Jervell, J. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.1.3572 · Cited by 176
Results of a European Multicentre Study with Sandostatin® LAR® in Acromegalic Patients
Lancranjan, I., Atkinson, A. B., & Sandostatin® LAR® Group# (1999) · Pituitary · doi:10.1023/a:1009980404404 · Cited by 166
Depot long-acting somatostatin analog (Sandostatin-LAR) is an effective treatment for acromegaly
Stewart, P. M., Kane, K. F., Stewart, S. E., Lancranjan, I., & Sheppard, M. C. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.80.11.3267 · Cited by 161
Prediction of efficacy of octreotide therapy in patients with acromegaly
Colao, A. A. L., Ferone, D., Lastoria, S., Marzullo, P., Cerbone, G., Sarno, A. D., Longobardi, S., Merola, B., Salvatore, M., & Lombardi, G. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.81.6.2356 · Cited by 147
Presurgical octreotide treatment in acromegaly
Stevenaert, A., Harris, A. G., Kovács, K., et al. (1992) · Metabolism · doi:10.1016/0026-0495(92)90031-5 · Cited by 147
Sandostatin® LAR®: A promising therapeutic tool in the management of acromegalic patients
Lancranjan, I., Bruns, C., Grass, P. N., Jaquet, P., Jervell, J., Kendall-Taylor, P., Lamberts, S. W. J., Marbach, P., Ørskov, H., Pagani, G. A., et al. (1996) · Metabolism · doi:10.1016/s0026-0495(96)90087-6 · Cited by 145
Long‐term therapy with long‐acting octreotide (Sandostatin‐LAR®) for the management of acromegaly
Davies, P. H. O., Stewart, S. E., Lancranjan, I., Sheppard, M. C., & Stewart, P. M. (1998) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1998.00389.x · Cited by 137
SASSOLAS, G., Harris, A. G., James-Deidier, A., & THE FRENCH SMS 201–995≌ACROMEGALY STUDY GROUP† (1990) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-71-2-391 · Cited by 136
Amato, G., Mazziotti, G., Rotondi, M., Iorio, S., Doga, M., Sorvillo, F., Manganella, G., Salle, F. D., Giustina, A., & Carella, C. (2002) · Clinical Endocrinology · doi:10.1046/j.0300-0664.2001.01438.x · Cited by 126
The impact of obesity on hormonal parameters in hirsute and nonhirsute women
Bernasconi, D., Monte, P. D., Meozzi, M., Randazzo, M., Marugo, A., Badaracco, B., & Marugo, M. (1996) · Metabolism · doi:10.1016/s0026-0495(96)90202-4 · Cited by 109
A comparison of lanreotide and octreotide LAR for treatment of acromegaly
Turner, Vadivale, Keenan, & Wass (1999) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1999.00853.x · Cited by 85
The effect of a new slow‐release, long‐acting somatostatin analogue, lanreotide, in acromegaly
Al‐Maskari, M., Gebbie, J., & Kendall-Taylor, P. (1996) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1996.8270836.x · Cited by 55
Long-Acting Octreotide LAR Compared with Lanreotide SR in the Treatment of Acromegaly
Kendall‐Taylor, P., Miller, M. A., Gebbie, J., Turner, S., & Al-Maskari, M. Y. (2000) · Pituitary · doi:10.1023/a:1009997506216 · Cited by 35
Cozzi, R. C., Barausse, M., Sberna, M., Lodrini, A., Franzini, A., Lasio, G. B., & Attanasio, R. (2000) · Pituitary · doi:10.1023/a:1012832230598 · Cited by 32
Razzore, P., Colao, A. A. L., Baldelli, R., Gaia, D., Marzullo, P., Ferretti, E., Ferone, D., Jaffrain‐Rea, M., Tamburrano, G., Lombardi, G., et al. (1999) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1999.00812.x · Cited by 22
Cited by
Acromegaly: An Endocrine Society Clinical Practice Guideline
Katznelson, L., Laws, E. R., Melmed, S., Molitch, M. E., Murad, M. H., Utz, A., & Wass, J. A. H. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2700 · Cited by 1,786
Self-citationClinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1)
Thakker, R. V., Newey, P. J., Walls, G. V., Bilezikian, J., Dralle, H., Ebeling, P. R., Melmed, S., Sakurai, A., Tonelli, F., & Brandi, M. L. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1230 · Cited by 1,477
Francis, G. L., Waguespack, S. G., Bauer, A. J., Angelos, P., Benvenga, S., Cerutti, J. M., Dinauer, C. A., Hamilton, J., Hay, I. D., Luster, M., et al. (2015) · Thyroid · doi:10.1089/thy.2014.0460 · Cited by 1,238
Raverot, G., Burman, P., McCormack, A., Heaney, A., Petersenn, S., Popovic, V., Trouillas, J., Dekkers, O. M., & _, _. (2018) · European Journal of Endocrinology · doi:10.1530/eje-17-0796 · Cited by 595
Somatostatin receptors: From signaling to clinical practice
Theodoropoulou, M., & Stalla, G. K. (2013) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2013.07.005 · Cited by 410
Metadata
- Authors
- Freda, P. U., Katznelson, L., van der Lely, A. J., Reyes, C. M., Zhao, S., & Rabinowitz, D.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2005-08
- Volume
- 90
- Issue
- 8
- Pages
- 4465-4473
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2160989555
- Cited by
- 346
- References
- 22
- FWCI
- 16.24
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.